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Abstract (250/250) 
Physical activity (PA) may be therapeutic for people with severe mental illness (SMI) who generally 
have low PA and experience numerous life style-related medical complications. We conducted a meta-
review of interventions and their impact on health outcomes for people with SMI, including 
schizophrenia-spectrum disorders, major depressive disorder (MDD) and bipolar disorder.  We 
searched major electronic databases until January 2018 for systematic reviews with/without meta-
analysis that investigated PA for any SMI. We rated the quality of studies with the AMSTAR tool, 
grading the quality of evidence, and identifying gaps, future research needs and clinical practice 
recommendations. For MDD, consistent evidence indicated that PA can improve depressive symptoms 
versus control conditions, with effects comparable to those of antidepressants and psychotherapy. PA 
can also improve cardiorespiratory fitness and quality of life in people with MDD, although the impact 
on physical health outcomes was limited. There were no differences in adverse events versus control 
conditions.  For MDD, larger effect sizes were seen when PA was delivered at moderate-vigorous 
intensity and supervised by an exercise specialist.  For schizophrenia-spectrum disorders, evidence 
indicates that aerobic PA can reduce psychiatric symptoms, improves cognition and various 
subdomains, cardiorespiratory fitness, whilst evidence for the impact on anthropometric measures was 
inconsistent.  There was a paucity of studies investigating PA in bipolar disorder, precluding any 
definitive recommendations. No cost effectiveness analyses in any SMI condition were identified. We 
make multiple recommendations to fill existing research gaps and increase the use of PA in routine 
clinical care aimed at improving psychiatric and medical outcomes. 
 
Key words: Physical activity, sedentary behaviour, exercise, psychosis, schizophrenia, severe mental 
illness, bipolar disorders, major depressive disorders  
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Introduction 
Serious mental illness, physical co-morbidity and premature mortality 
Severe mental illnesses (SMI), defined as schizophrenia-spectrum disorders, bipolar disorder (BD) and 
major depressive disorder (MDD), are leading causes of years lived with global disability and are of 
considerable public health importance 1. In addition to the impact of the mental health symptoms and 
reduced daily life functioning, people with SMI are at increased risk of premature mortality by between 
10 to 20 years compared to age- and sex-matched controls 2-5. While suicide accounts for a concerning 
portion of the early mortality 6,7, there is increasing recognition that physical disorders account for 
approximately 70% of these premature deaths 3,8. Of notable concern, cardiovascular and metabolic 
diseases appear to greatly increase the risk of early death in those with SMI9, which is of particular 
importance, given the high prevalence of these diseases in SMI 9-11.  People with SMI are also at 
increased risk of various other physical comorbidities, such as respiratory disease 12,13, poor bone health 
14 and physical multimorbidity 15.  Moreover, people with SMI typically experience pronounced 
cognitive impairment, which often worsens over time 16-18 and for which treatment approaches remain 
limited 19,20.   
Current treatment for mental health symptoms and functioning largely revolves around psychotropic 
medication 21,22 and/or psychotherapeutic interventions 23-25. Whilst both of these dominant approaches, 
alone and in combination, have demonstrated treatment efficacy on mental health symptoms 26, their 
impact on the rising physical health burden in this population is limited, and psychotropic medication 
may even have an adverse relationship with cardiometabolic/physical health 8,9.  In addition, 
antipsychotic medication has been associated with reduced grey matter volume in people with 
schizophrenia 27 while psychotherapeutic interventions appear to have limited efficacy for cognitive 
impairment in this population 28. 
Established benefits of physical activity in the general population 
In the general population, there is evidence that physical activity is equally effective as frontline 
pharmacological interventions, such as statins and beta-blockers, in preventing cardiovascular disease 
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mortality 29.  Moreover, there is consistent evidence that physical activity and exercise can decrease the 
risk of developing cardiovascular and metabolic disease 30-32 and reduce inflammatory parameters, such 
as C-reactive protein, 33,34 which are commonly raised in people with SMI 35.  Conversely, higher levels 
of sedentary behaviour (characterized by an energy expenditure ≤1.5 metabolic equivalents (METs), 
while in a sitting, reclining or lying posture during waking hours 36) are independently associated with 
an increased risk of diabetes, cardiovascular disease and premature mortality 37.  In the general 
population, there is also evidence that lower levels of cardiorespiratory fitness are a more accurate 
determinant of premature death than body mass index (BMI) 38.  Moreover, there is evidence that 
aerobic exercise is effective in improving cognitive function in the general population 39-43 including 
potentially increasing hippocampal volume 44.  In addition, a recent global meta-analysis has 
demonstrated that higher levels of PA confers protection from the development of  depressive symptoms 
and MDD45.   
 
Low levels of physical activity and fitness 
Despite the aforementioned, there is evidence to suggest that less than half of people with SMI 
(schizophrenia 46, bipolar disorder 47 and major depression 48 49)  meet recommended physical activity 
levels of 150 minutes of moderate-vigorous physical activity per week 50.  Moreover, each of these 
populations engage in remarkably high levels of sedentary behaviour 46-48 and have low levels of 
cardiorespiratory fitness 51.  People with SMI experience, a number of barriers from engaging in 
physical activity exist, such as side effects of medications, complications from obesity/poor physical 
health52,53, lack of resources/professional support54, various motivational factors,55 which calls for 
targeted interventions in this highly sedentary population56-58.   
In light of the above, we set out to conduct an evidence-based guideline meta-review and position 
statement on the use of physical activity and exercise among people with SMI.   
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Aims 
The overall aims of this meta-review and position statement were as follows: First, to establish the 
benefits of physical activity / exercise across all categories of severe mental illness (SMI), using top-
tier evidence from published systematic reviews and meta-analyses. Second, examine how the benefits 
of physical activity may differ across specific SMIs, including schizophrenia-spectrum disorders, BD 
and MDD. Finally, to use these findings to provide guidance for clinical practice, policy and future 
research.  
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Methods 
Guidance development process  
This guidance paper was performed in accordance with the PRISMA guidelines 59 following a pre-
determined, published protocol (PROSPERO registration CRD42017068292).  Moreover, the current 
guidance was conducted in accordance with the European Psychiatric Association (EPA) guidelines 
framework and wherever possible, adopted guidance based on the findings from systematic reviews and 
meta-analyses 60.   
Searches and study selection 
Two independent authors searched from inception to 15th January 2018 Medline/ Pubmed, PsychInfo, 
EMBASE and the Cochrane database for systematic reviews (with and without meta-analyses) of 
studies investigating physical activity/ exercise among people with SMI, schizophrenia-spectrum 
disorders, BD or MDD. The search terms included (exercise or aerobic exercise or physical activity or 
resistance training) and (schizophrenia or psychosis or psychotic or major depression or depression or 
bipolar disorder or serious mental illness or serious mental disorder).  The reference lists of included 
articles were also hand-searched.   
Type of studies eligible for inclusion 
We followed the European Psychiatric Association manual for identifying and conducting this review 
and evidence was considered in a hierarchical approach, going from systematic reviews to the highest 
level of meta-analyses.  In the absence of these two data sources for particular outcomes, we sought to 
identify newer randomised/controlled trials.   
The specific inclusion criteria were: 1) systematic reviews (with or without meta-analyses) that 
synthesised randomised, controlled clinical trials or randomised control trials (RCTs) or controlled 
clinical trials (CCTs); 2) physical activity/ exercise interventions, including aerobic, high intensity and 
resistance exercise as monotherapy or in conjunction with other treatment options, including 
psychotropic medication or psychological therapies; 3) systematic reviews of PA, which included 
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people with pooled SMI or schizophrenia-spectrum disorders, BD or MDD, confirmed through 
validated assessment measures (e.g. Diagnostic and Statistical Manual of Mental Disorders 61(DSM), 
International Classification of Diseases 62 (ICD) criteria), in any setting; 4) systematic reviews, which 
included a non-active/ non-exercise control group (e.g., does not include physical activity).  We 
excluded mind-body physical activity interventions, such as yoga and tai-chi, since these activities are 
presumed to exert beneficial effects on mental health through additional factors distinct from the 
physical activity itself.  
Definition of exercise and physical activity 
We included systematic reviews investigating the benefits of exercise or physical activity in people with 
SMI.  Exercise was defined as “planned, structured, and repetitive and has as a final or an intermediate 
objective the improvement or maintenance of physical fitness.”63.  Within this definition, we included 
aerobic exercise, high intensity exercise, resistance exercise and mixed exercise (i.e., aerobic and 
resistance exercise).  Physical activity was defined as “any bodily movement produced by skeletal 
muscles that results in energy expenditure” 63.  We considered exercise/physical activity studies used 
as monotherapy or in combination with other types of treatment, e.g., psychotropic medication or 
psychological interventions.   
Outcomes 
As indicated in the EPA guidelines manual 60, as a first choice in the hierarchy of evidence, we drew 
evidence from systematic reviews of exercise/ physical activity interventions, including meta-analyses 
and/ or RCTs/ CCTs that considered the outcomes listed below.  In accordance with our published 
protocol, we included data from the largest and/or most recent paper investigating each type of PA and 
each outcome in any population.   
Primary outcomes 
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The primary outcomes focused on changes in the severity of symptoms, which characterise the included 
psychiatric disorders. For example, positive and negative symptoms in people with schizophrenia-
spectrum disorders; and depressive symptoms in people with MDD or BD.   
Secondary outcomes 
We were interested in a range of secondary outcomes, including: 
• Physical health factors, e.g., cardiovascular or metabolic parameter changes, anthropometric 
measures (e.g., BMI, waist circumference) or body composition measures (e.g., amount of 
intra-abdominal and cardiac adipose tissue).  
• Cardiorespiratory fitness (expressed as percentage maximal or peak oxygen uptake), muscular 
fitness.  
• Increasing physical activity levels or decreasing sedentary behaviour.   
• Biomarkers, e.g., HbA1C, C-reactive protein, brain derived neurotrophic factor (BDNF), 
interleukin-6.   
• Cognitive functioning, e.g. performance in neuropsychological tests 
•  Brain structure and connectivity, e.g., determined through magnetic resonance imaging or 
diffusor tension imaging changes. 
• Quality of life and functioning.  
• Dropout rates and predictors from physical activity interventions. 
• Adverse events (e.g., injuries sustained from PA) 
• Economic evaluations.   
Data extraction 
Data extraction was conducted by two authors and reviewed by a third author.  We extracted data from 
systematic reviews and meta-analyses of RCTs/ CCTs investigating exercise interventions, including: 
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Number of studies included, number of participants in each arm, participant demographics, length of 
follow-up, details of the exercise intervention, statistical analyses conducted, effect size information, 
heterogeneity, publication bias and details of any meta regression and subgroup analyses. 
Where a systematic review was not available for an outcome, we narratively summarised information 
from newer RCTs/ CCTs in the manuscript text, noting the study design, sample size, description of the 
intervention and control group, intervention effect and any harms and dropout rates.   
Quality assessment and grading of evidence 
Two independent authors assessed the quality of systematic reviews and meta-analyses with the 
AMSTAR tool 64,65.  In addition, we assessed the quality of evidence using the SIGN (2011) 
recommendations as indicated by the EPA guidelines 60 and in accordance with a recent published EPA 
guidelines on psychotherapy for depression 24.  Specifically, each included study was graded from 1++ 
(highest quality) to 4 (lowest quality) (see table 1).  Based on the quality of evidence, we graded 
recommendations according to best practice (table 2).   
Table 1 Grading of evidence in accordance with SIGN (2011 (and adapted from 24) 
Grade Description 
1 ++ High-quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews or RCTs with a low risk of bias 
1−a Meta-analyses, systematic reviews or RCTs with a high risk of bias 
2 ++ High-quality systematic reviews of case control or cohort studies. High-quality case control or 
cohort studies with a very low risk of confounding or bias and a high probability that the 
relationship is causal 
2+ Well-conducted case control or cohort studies with a low risk of confounding or bias and a 
moderate probability that the relationship is causal 
2−a Case control or cohort studies with a high risk of confounding or bias and a significant risk that 
the relationship is not causal 
3 Nonanalytic studies, e.g. case reports, case series 
4 Expert opinion 
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Table 2 Grading of recommendations, modified from the SIGN (2011) and adopted from 66 
Grade Description 
A At least one meta-analysis, systematic review, or other study rated at low risk of bias 
B A body of evidence including studies rated as 2, directly applicable to the target population, and 
demonstrating overall consistency of results; or extrapolated 
evidence from studies rated as I or II 
C  A body of evidence including studies rated as II–III, directly applicable to the target population and 
demonstrating overall consistency of results.   
D Good practice point recommended good practice based on the clinical experience of the Guidance 
development group and arrived at through consensus 
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Results 
Search results and included studies 
The initial database searches acquired 2,722 hits and 2,081 were reviewed at the abstract level.  
Subsequently, we reviewed 145 full texts, and 125 were excluded with reasons (see figure 1).  Overall, 
20 systematic reviews and meta-analyses were included in this guidelines document, which included 
studies that provided effect sizes for the benefit of exercise for SMI 51 (N=1), schizophrenia-spectrum 
disorders 67-73 (N=7), BD 74,75(N=2) and MDD 76-85 (N=10).   
Figure 1 here 
Details of the included systematic reviews representing participants, interventions, outcomes, main 
results, considerations, AMSTAR scores and level of evidence scores are summarized in table 3 for 
schizophrenia-spectrum disorders and mixed SMI participants, and in table 4 for MDD and BD 
participants.  Details of the results are described below for each population group.   
Insert table 3 and table 4 here 
Pooled SMI  
One meta-analysis provided non-overlapping data on exercise for people with pooled SMI 51,86.  It was 
demonstrated that aerobic exercise improved fitness in pre and post-test studies among people with 
schizophrenia-spectrum disorders and MDD (Hedges’ g = 0.33, 95 % CI 0.21–0.45, p = 0.001, 13 
studies) 51 (AMSTAR 7, evidence level -1).  Improvements in fitness were not accompanied by 
improvements in BMI.  Meta regression showed that higher (vs, low or moderate) intensity 
interventions and those delivered by qualified professional predicted better outcomes.  In 5 RCTs, 
exercise improved fitness versus control (Hedges’ g = 0.43, 95 % CI 0.10–0.76, p = 0.01; n = 109).   
Dropout, adverse events and economic evaluations of exercise interventions in pooled SMI 
No information was reported on dropout rates, adverse events or economic evaluations in people with 
SMI.   
Schizophrenia-spectrum disorders 
In total, 7 systematic reviews and meta-analyses reported the benefits of exercise for schizophrenia-
spectrum disorders 67-73.  There was broad variation in the frequency, intensity, type and time of the 
interventions across the included systematic reviews and meta-analyses (Table 3).  The mean AMSTAR 
score for the included reviews was 6 (range 4-10).   
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A summary of the main results for exercise interventions in schizophrenia are presented in table 5.  In 
a meta-analysis of 8 RCTs 68 (AMSTAR 5, evidence level -1) and 659 patients with schizophrenia-
spectrum disorders, exercise reduced total psychiatric symptoms when interventions used at least 90 
min of moderate-to-vigorous physical activity (MVPA) per week (SMD: 0.72, 95% confidence interval 
−1.14 to −0.29 ).  Ninety minutes of MVPA was also associated with reduced positive (SMDs -0.54, 
95% CI -0.95 to -0.13) and negative symptoms (SMD-0.44, 95% CI -0.78 to -0.09).  Pooled data from 
four RCTs found that exercise had no significant effect on reducing BMI (MD: -0.98 kg/m2; 95% CI -
3.17 to 1.22 kg/m2, N=4).  Narrative findings regarding the influence of exercise on additional 
cardiometabolic parameters, such as waist circumference, high density lipoprotein levels and 
triglycerides, were inconsistent.  Data from a narrative synthesis across 3 RCTs found that exercise also 
improved quality of life in people with schizophrenia-spectrum disorders.  The key consideration from 
this systematic review was that optimal effects of exercise interventions are derived when people 
achieve over 90 minutes of MVPA per week.   
A meta-analysis from 10 studies 67 (AMSTAR 5, evidence level -1) including a sample of 186 in the 
intervention and 199 in the control group, found that exercise improved global cognition (g = 0.33, 95% 
CI = 0.13–0.53, P = .001). Meta-regression analyses indicated that greater improvements in global 
cognition were moderated by greater amounts of weekly exercise and when interventions were 
delivered by exercise professionals (e.g., physiotherapists, BSc level qualified exercise scientists).  Sub-
group analyses found that exercise improved cognitive domains of working memory (g = 0.39, P = .024, 
N = 7, n = 282), social cognition (g = 0.71, P = .002, N = 3, n = 81), and attention/vigilance (g = 0.66, 
P = .005, N = 3, n = 104).  A systematic review of 14 trials 69 investigated the pro-cognitive mechanisms 
of exercise in schizophrenia-spectrum disorders (AMSTAR 4, evidence level -1).  The review suggested 
that exercise may increase brain volume, although there was a lack of consistency regarding which 
regions.  One region that has been implicated is the hippocampus 87 although a meta-analysis of four 
studies did not support this hypothesis 44.  This review 69 also found inconsistent evidence for an effect 
of exercise on BDNF levels, which is consistent with a meta-analysis 72 (AMSTAR 10, evidence level 
-1) also finding that exercise did not influence BDNF levels.  Thus, whilst there seems reasonable 
evidence that exercise does improve cognition in schizophrenia-spectrum disorders 67, the underlying 
mechanisms are not yet clear.   
A recent systematic narrative review 88 investigated the influence of strength training on outcomes in 
schizophrenia-spectrum disorders (AMSTAR 4, evidence level -1).  Across 6 studies (3 RCTs) the 
authors found tentative evidence that strength training over time can improve muscle strength, walking 
performance and reduce psychopathology symptoms.  This systematic review was complimented by 
another systematic review 71 (AMSTAR 7, evidence level -1) that found evidence that combined aerobic 
and strength training (7 RCTs) may improve strength, symptoms of schizophrenia and mental health, 
but not cardiovascular fitness.   
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A narrative systematic review 70 across 10 intervention studies (5 RCTs) (AMSTAR 5, evidence level 
-1) found that in those with schizophrenia-spectrum disorders, walking may reduce weight, BMI and 
body fat in the short-term.  The authors noted that walking appeared to be safe, although the evidence 
was noted to be of medium-high risk of bias in the included studies.  
Finally, a meta-analysis of seven studies (3 RCTs) 73 (AMSTAR 8, evidence level -1) found that over a 
12 week exercise intervention, aerobic exercise improved cardiorespiratory fitness versus control 
conditions (g = 0.41, 95%  = CI 0.05 to 0.82, P = 0.028).  
  
Insert table 5 
Dropout, adverse events and economic evaluations of exercise interventions in schizophrenia-
spectrum disorders 
A meta-analysis of 19 RCTs and 594 schizophrenia-spectrum disorder patients 89 demonstrated that 
26.7% [95% confidence interval (CI)=19.7%-35.0%] of patients dropped out of interventions, more 
than double reported in non-active control interventions (odds ratio=2.15, 95% CI=1.29-3.58, P=.003).  
Factors influencing lower dropout in meta-regression analyses included supervision from a recognized 
exercise professional and including a motivational component.   
Surprisingly, very little information is available on the potential harms or adverse events from exercise 
in schizophrenia-spectrum disorder patients.  Specifically, the following papers did not report harms 67-
69,71,72,88.  Only one study 70 reported potential harms and found that walking was not associated with 
adverse events in schizophrenia-spectrum disorders.   
To the best of our knowledge, there have been no studies with an economic evaluation of the cost and 
value of delivering exercise interventions in schizophrenia-spectrum disorders.   
Major depression  
In total 10 systematic reviews and meta-analyses reported the benefits of exercise for MDD 76-85.  The 
mean AMSTAR score for the included reviews was 9.1 (range 3-10).  Full details of the included 
systematic reviews are summarized in table 4.   
A summary of the effects of exercise in MDD are reported in table 5.  In a comprehensive Cochrane 
review 83 including exercise trials, the authors found that exercise was effective in reducing depressive 
symptoms versus control conditions (Hedge’s g=-0.68, 95% CI -0.92 to -0.44, p=0.001, I²=67.99, k=23) 
(AMSTAR 11, evidence level 1+).  Exercise was effective in studies with (Hedge’s g = -0.40, 95% CI 
= -0.70 to -0.11, P = 0.01, k=10) or without (Hedge’s g=-0.91, 95% CI = -1.22 to -0.61, P < 0.001, k = 
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13) blinded outcome, with (Hedge’s g=-0.56, 95% CI -0.87 to -0.25, p<0.001, k=12) or without 
(Hedge’s g =-0.80, 95% CI = -1.15 to -0.46, p<0.001, k=11) intention-to-treat, and in studies comparing 
exercise with no intervention (Hedge’s g = -1.24, 95% CI = -1.83 to -0.65, k = 4), and with usual care 
(Hedge’s g = -0.48, 95% CI = -0.8 to -0.16, k = 4).  There was no difference in exercise versus 
psychological interventions (Hedge’s g = -0.22, 95% CI -0.65 to 0.21, k=4), or antidepressant treatment 
(Hedge’s g = -0.08, 95% CI = -0.33 to 0.18, k = 3), indicating exercise demonstrated comparable 
efficacy versus these established interventions.  However, information on symptom severity was not 
available.  Of note, beneficial effects were confirmed when considering only studies with blinded 
outcomes (Hedge’s g = -0.40, 95% CI -0.69 to -0.11, P = 0.01, k = 10), but not when considering blinded 
outcomes with both adequate allocation concealment and intention-to-treat together (Hedge’s g = -0.26, 
95% CI = -0.61 to 0.08, P = 0.14, k = 6).  Also, at longer follow-up (mean 10.75 month) no significant 
effect was reported (Hedge’s g =-0.22, 95% CI -0.53 to 0.09, P = 0.16, k = 7).    
 
More recently, a meta-analysis 81 (AMSTAR 10, evidence level 1+) attempted to address some of the 
criticisms of the Cochrane review 83, such as the inclusion of a number of in-eligible trials, comparing 
exercise versus other exercise interventions, and the absence of adjusting for publication bias.  The 
authors 81 found across 25 RCTs (intervention 757, control 730) that exercise versus non-active 
interventions over a mean of 14 weeks resulted in a large improvements of depressive symptoms (SMD 
= 1.11, 95% CI % =  0.79-1.43, k = 25) with a failsafe number of 1057. Exercise was effective both 
when the diagnosis was made according to DSM61 (SMD = 1.14, 95% CI = 0.46-1.81,  P < 0.001, I² = 
88.5, k = 9) or depressive symptoms (SMD = 0.801, 95% CI = 0.49-1.11,  P < 0.001, I² = 68.5, k = 14), 
high (SMD = 0.882, 95% CI = 0.221-1.544,  P = 0.009, I² = 90.1, k = 4) and low (SMD = 1.033, 95% 
CI = 0.66-1.41,  P < 0.001, I² = 79.2, k = 21) quality studies, outpatients (SMD = 1.123, 95% CI = 0.77-
1.47,  p<0.001, I2=84.6, k=21) and inpatients (SMD = 0.553, 95% CI = 0.167-0.938,  P = 0.005, I² = 0, 
k =3), but not in a nursing home (k=1). Exercise was effective at moderate (SMD=1.33, 95% CI 0.46-
2.197,  P = 0.003, I² = 83.4, k = 6) and vigorous (SMD = 1.342, 95% CI = 0.437-2.246,  P = 0.004, I² = 
91.1, k = 7), but not at light intensity (k = 3), and was effective as aerobic exercise (SMD = 1.045, 95% 
CI = 0.653-1.437,  P < 0.001, I² = 80.97).  The same author group also reported that exercise was 
effective in improving depressive symptoms in older adults (SMD = -0.90, 95%CI = 0.28-1.51, P = 
0.004, I2 = 81.63, P = 0.001, k = 8).  In addition, a recent meta-analysis 82 (AMSTAR 10, evidence level 
1+) confirmed that exercise was effective in reducing depressive symptoms, including those with and 
without blinded outcomes and with or without intention-to-treat analysis (see table 4).  The authors 82 
also confirmed results from the Cochrane review that exercise was as effective as psychological 
intervention and antidepressant treatment for depressive symptoms (see table 4).  In another review 
regarding mental health symptoms 84 (AMSTAR 7, evidence level -1), exercise increase response but 
not remission of MDD (see table 4).  Finally, a trial sequential meta-analysis 85 (AMSTAR 10, evidence 
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level -1) confirmed earlier results that exercise was effective for MDD (SMD −0.66, 95% CI −0.86 to 
−0.46; p<0.001).  Moreover, the authors tentatively suggested that when pooling four RCTs of “high 
quality” with a trial sequential meta-analysis (two of which were their own studies and concerns have 
been raised about the inappropriate use of active control groups 90) that exercise may no longer be 
effective.   
 
A narrative systematic review 76 (AMSTAR 4, evidence level -1) suggested that exercise did not 
influence anxiety symptoms, oxygen uptake, blood glucose, body fat or functioning versus control 
conditions, although all of these outcomes were limited to one study only.  A recent meta-analysis of 8 
RCTs 77 (AMSTAR 10, evidence level -1) found that aerobic exercise was not effective for global 
cognition (Hedges' g = 0.07, 95% CI = -0.08 to 0.24, I² =0%) nor for any cognitive subdomains.  A 
meta-analysis of 7 RCTs 78 demonstrated that aerobic exercise over approximately 12 weeks improved 
cardiorespiratory fitness (Hedge’s g = 0.64, 95%CI = 0.32–0.96, P = 0.001, I2 = 67%, k = 8) (AMSTAR 
10, evidence level 1+).  Exercise also improved quality of life (QOL) overall (SMD = 0.39, 95%CI = 
0.47–0.74, P = 0.002, I²= 0.0, k = 5) in addition to physical (SMD = 0.53, 95%CI = 0.22–0.84, P = 
0.001, I²= 00.00, k = 5) and psychological (SMD = 0.53, 95%CI = 0.22–0.85, P = 0.001, I²= 4.89, k = 
5) QoL domains.  However, no effect was seen in social (SMD=0.28, 95%CI = -0.13 to 0.71,p=0.18, 
I²= 13.04, k = 5) or environmental QoL domains (SMD = 0.36, 95%CI = -0.12 to 0.85,P = 0.14, 
I²=30.75, k = 5).   
Dropout, adverse events and economic evaluations of exercise interventions in major depression 
A meta-analysis of 31 RCTs 91 reported that the dropout rate adjusted for publication bias was 17.2% 
(95%CI = 13.5-21.7) in MDD only. In MDD participants, higher baseline depressive symptoms (β = 
0.0409, 95%CI = 0.0809-0.0009, P = 0.04) predicted greater dropout, whilst supervised interventions 
delivered by physiotherapists (β = -1.2029, 95%CI = -2.0967 to -0.3091, P = 0.008) and exercise 
physiologists (β = -1.3396, 95%CI = -2.4478 to -0.2313, P= 0.01) were associated with lower dropout. 
A comparative meta-analysis (N = 29) established dropout was lower in exercise than control conditions 
(OR = 0.642, 95%CI = 0.43-0.95, P = 0.02).   
Information on adverse events was limited in the reported systematic reviews.  One review 83 reported 
that 6 RCTs reported adverse events.  These included muscular pain/symptoms, fatigue and increased 
depressive symptoms, but there was no difference versus those reported in control conditions.  Another 
review confirmed there were no differences in serious or non-serious adverse events versus control 
conditions 85.   
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To the best of our knowledge, there have been no economic evaluations of the cost effectiveness of 
delivering exercise interventions for people with MDD.   
Bipolar disorder 
In total, 2 systematic reviews reported the benefits of exercise for BD 74,75.  Both systematic reviews 
were rated with an AMSTAR score of 4. The evidence was very limited because of the number of 
eligible studies in BD patients.  A summary of the effects of exercise in BD are reported in table 5.  One 
review identified only two studies that included people with BD, 74 finding some evidence that exercise 
may improve depressive symptoms and reduce stress, but observing no influence on function, general 
symptoms or clinical global impression.  In the other systematic review, only one study was identified 
in BD patients, 75 which suggested that exercise decreased body weight more than in the control group.   
 
Dropout, adverse events and economic evaluations of exercise interventions in bipolar disorder 
We found no reports in the included systematic reviews of dropout rates, adverse events or economic 
evaluations.   
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Recommendations 
Based on our extensive systematic review of the literature, we have made ten recommendations for 
future research (where gaps are evident) and clinical practice based on the degree of evidence and grades 
in line with the SIGN methodology checklist.  In line with the SIGN and previous EPA guidelines, 66 
recommendations were graded as A (meta-analysis, systematic review or other level 1 evidence), B 
(meta-analysis, systematic review or RCT with moderate or high risk of bias), C (large body of evidence 
from intervention studies, observational data), or D (expert opinion).  
Research Recommendations  
1. For all SMI groups, more research is needed into the effects of PA interventions during 
the prodromal and early phase of illness onset (Based on expert opinion, D)   
The majority of research on the effect of PA has been conducted in patients with established SMI.  
However, in the case of physical health outcomes, there is evidence from the general population that 
using lifestyle changes to prevent deterioration in metabolic health is a more feasible and effective 
approach than attempting to reverse chronic cardio-metabolic diseases 92.  Research is needed to 
determine whether exercise interventions in the early stages of SMI likewise have a positive effect on 
physical and mental health outcomes. Furthermore, research is needed to assess whether using exercise 
to improve mental health and psychosocial functioning shortly after illness onset may reduce the 
likelihood of long-term functional disability, or increase the likelihood of achieving a full and sustained 
recovery.  Given this situation, we recommend a greater research emphasis on evaluating PA 
interventions during the prodromal phase and first/early presentation of SMI.   
2. To optimize treatment ‘reach’, research should focus on establishing pragmatic, scalable 
methods for delivering PA as a treatment for SMI (Based on expert opinion, D). 
Research priorities should shift from efficacy studies to pragmatic effectiveness trials. Specifically, 
there is a need to develop replicable and scalable methods for delivering PA interventions to people 
with SMI, in a format which is accessible, engaging and effective for large numbers of patients. There 
is sufficient evidence to indicate that the most effective and engaging interventions will be those that 
are (i) delivered by qualified exercise professionals (rather than mental health staff), and (ii) delivered 
at sufficient levels of intensity to significantly improve physical capacities, such as cardiorespiratory 
fitness.  Whilst the evidence is clear that better treatment outcomes and less dropout are achieved across 
SMI for PA interventions delivered by qualified exercise professionals, the potential benefits of training 
mental health staff (e.g., psychologists, psychiatric nurses - of whom there are many more) on principles 
of PA in delivering exercise interventions should be evaluated.   
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3. Controlled trials of exercise for SMI should aim to determine the optimal frequency, mode 
and dose-response of PA needed to treat SMI and should focus on implementation and 
culture in clinical practice  and prevent adverse events (Based on expert opinion, D) . 
Whilst there is some evidence from exercise trials in MDD that moderate/high intensity PA is associated 
with larger effect sizes than low-intensity PA for mental health and cardiorespiratory fitness 81 and for 
better cognitive outcomes in established schizophrenia 67, more research is specifically required to 
ascertain the optimum frequency, intensity, time and type of interventions in each SMI, although it is 
important to note this may vary for each individual based on their preferences and/or illness 
characteristics.  In addition, very few systematic reviews reported adverse events.  Future studies should 
carefully assess any adverse events, particularly in light of any cardiovascular risk and events.  This 
may include screening for cardiovascular risk and appropriately individualizing the optimal frequency 
and intensity of PA, which has been covered extensively elsewhere 93,94.  Of most importance, future 
translational research focussing on implementation into clinical practice is urgently required.  This 
should involve determining optimal motivational frameworks and understanding cultures in practice 
that enable the optimal uptake and maintenance of PA.    
4. Research examining the effects of interventions to reduce sedentary behaviors and 
increase PA is needed (Based on expert opinion, D). 
Recent meta-analyses have demonstrated that people with SMI are highly sedentary 49.  With increasing 
evidence that sedentary behaviours have independent adverse effects on somatic health37, research is 
needed to investigate if sedentary behaviors can be reduced in this population and tease out the relative 
importance of reducing sedentary behaviours in the context of structured exercise interventions.  
5. The underlying neurobiological mechanisms of PA in SMI are inadequately understood 
and require further investigation (Based on expert opinion, D).  
Several tenable theories have been proposed to explain the positive effects of PA in SMI, but the results 
are unclear. In particular, it is uncertain what ‘dose’ of exercise is needed to elicit the purported 
biological mechanisms, and how these interact with the psycho-social benefits of exercise. Future 
research should explore the underlying mechanisms of PA efficacy in all SMIs.  
6. Undertake long term and cost-effectiveness analyses of PA interventions (Based on expert 
opinion, D). 
Whilst there is an increasing evidence base on the efficacy of PA for SMI, there is an absence of cost 
effectiveness studies.  Undertaking cost-effectiveness research should be a priority.  There are also 
relatively few long term (>12 months) trials, although a recent large RCT lasting 12 months 
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demonstrated that PA was as effective as internet-delivered CBT, and both were better than the control 
group 95.   
Clinical practice recommendations 
 
7. Physical activity should be used as a treatment for mild-moderate depression to improve 
symptoms and physical fitness (good evidence, A). 
There is now an abundance of data demonstrating that as an adjunctive treatment, PA is effective in 
reducing depressive symptoms in people with MDD.  Specifically, based on current evidence, we 
recommend that intervention consists of 2-3 sessions of supervised aerobic and/or aerobic and 
resistance training exercise a week of 45-60 minutes duration of moderate intensity.  The literature 
regarding resistance training as a standalone intervention for MDD is limited, but growing.  To date, 
there have been limited direct head-to-head comparisons of different types of exercise interventions (in 
terms of frequency, intensity, time and type), which precludes definitive conclusions being made about 
the superiority or better acceptability (or lack thereof) of specific forms of PA,  and our current 
knowledge is derived primarily from interventions comparing “PA” versus non-active interventions.  In 
order to achieve optimal outcomes and less dropouts, the evidence base indicates that 
physiotherapists/qualified exercise professionals should lead and supervise PA interventions. However, 
since qualified exercise professionals are not available in each setting, the efficacy and effectiveness of 
training other personnel in the principles and delivery of PA requires further study. Finally, there is also 
good evidence that PA can improve cardiorespiratory fitness in people with depression78.   
 
8.  Physical activity should be utilised as an adjunctive treatment for schizophrenia-
spectrum disorders, to improve symptoms, cognition and QoL (good evidence, B) 
Our review indicates that PA is an effective adjunct to improve symptoms, global cognition and various 
subdomains, and quality of life in schizophrenia-spectrum disorders.  In fact, at least in indirect 
comparison, the benefits of PA for cognition seem to be comparable to other psychological 
interventions (e.g., cognitive remediation) and should be a core part of multidisciplinary treatment.  The 
most consistent evidence to date is available for aerobic exercise that meets 150 minutes of moderate 
to vigorous PA per week.  There are limited data available specifically on resistance training for people 
with schizophrenia-spectrum disorders and data are inadequate comparing the potential superiority of 
various forms of PA to each other.  Nonetheless, interventions supervised by qualified professionals, 
with a motivational component result in less dropout.   
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9. Physical activity should be used to improve physical health in people with SMI (Some 
evidence, C) 
Whilst there is an abundance of evidence for PA to prevent the onset of a number of physical diseases 
(e.g., cardiovascular disease) and to have the potential to improve these conditions in the general 
population, the evidence base in individual SMIs is mixed, possibly due to poor adherence and the 
paucity of studies that have targeted this important topic.  However, there is some indication that PA 
can improve cardiovascular disease risk markers in people with SMI.  Given the weight of evidence in 
the general population and some initial data in people with SMI, we advocate that PA forms a core part 
of preventing and managing poor physical health in people with SMI.  Nevertheless, more research 
should be performed in this area to further strengthen the support for this recommendation. 
 
10. People with SMI should be screened for PA habits in primary and secondary care (Based 
on expert opinion, D). 
In light of the evidence of the health benefits of PA, the use of brief PA screening in primary/secondary 
care in the general population as a health indicator and to manage chronic conditions is common 96,97.  
A previous systematic review 98 identified, no specific self-report PA tool has robust psychometric 
properties and can be advocated for routine use in clinical practice.  Nonetheless, given that people with 
all SMIs are known to engage in low levels of PA and high SB 49 a routine measure of PA to monitor 
PA habits could prove useful.  To the best of our knowledge, only one PA tool, the SIMPAQ 99 has 
been developed specifically for use to measure PA and SB in clinical practice.  Given the above 
literature, we advocate that people with SMI are screened for PA and advised on increasing activity 
levels in primary and secondary services.  Further research is needed to identify a practical and valid 
measure that can be used in clinical care. 
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Conclusion 
There is now considerable empirical evidence supporting the use of PA interventions in the treatment 
of MDD and schizophrenia-spectrum disorders.  Specifically, our meta-review supports the use of 
aerobic exercise of moderate-vigorous intensity at a frequency of 2-3 times a week, ideally supervised 
by qualified professionals and achieving 150 minutes of MVPA per week in order to improve outcomes 
in people with MDD and schizophrenia-spectrum disorders.  There is also some evidence that a 
combination of aerobic and resistance training meeting the above frequency, intensity and time criteria 
can improve outcomes in people with MDD and schizophrenia-spectrum disorders.  There is growing 
interest in the use of resistance training as a standalone PA intervention.  However, the literature is 
equivocal in both MDD and schizophrenia-spectrum disorders.  Currently, the evidence for use of PA 
in patients with BD is promising, but limited by the paucity of studies, and it is therefore not possible 
to reach any firm conclusions regarding population-specific recommendations above and beyond those 
aimed at the general population.  Across all disorders, there have been limited interventions that have 
specifically compared various forms of PA versus one another, which again precludes reaching any 
firm conclusions based on the relative superiority of the different forms of PA, and one should be aware 
that our knowledge to date is largely drawn from studies comparing PA versus non-active control 
conditions. The underlying psychobiological mechanisms of the benefits derived from PA are only 
poorly understood, and further research is needed to elucidate causal relationships between exercise and 
improvements in the mental and physical domains of people with SMI. Finally, due to absence of data, 
it is currently unclear whether PA is a cost-effective treatment option, and more work is needed to 
establish the financial aspects of this mode of treatment compared with conventional approaches, taking 
into account the various domains of lives of people with SMI that PA can affect.  
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